Audeo Oncology (Audeo Oncology) EPS (Basic) : $0.00 (TTM As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology EPS (Basic)?

Audeo Oncology's basic earnings per share (Basic EPS) for the three months ended in Sep. 2012 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.

Audeo Oncology's EPS (Diluted) for the three months ended in Sep. 2012 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.

Audeo Oncology's EPS without NRI for the three months ended in Sep. 2012 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2012 was 0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Audeo Oncology EPS (Basic) Historical Data

The historical data trend for Audeo Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology EPS (Basic) Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

EPS (Basic)

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
EPS (Basic)	-	-	-	-

Audeo Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Audeo Oncology's Basic EPS for the fiscal year that ended in Jun. 2012 is calculated as

Basic EPS (A: Jun. 2012 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-9.952	-	0)	/	0
	=

Audeo Oncology's Basic EPS for the quarter that ended in Sep. 2012 is calculated as

Basic EPS (Q: Sep. 2012 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.135	-	0)	/	0
	=

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Audeo Oncology (DELISTED:AURX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Audeo Oncology EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » EPS (Basic)

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.